-+ 0.00%
-+ 0.00%
-+ 0.00%

Galapagos NV Reports 96% Complete Response Rate in Phase 2 CAR T-Cell Therapy Trial for Mantle Cell Lymphoma

路透·12/08/2025 06:30:17

登錄查看新聞詳情